Literature DB >> 8279092

Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).

T M de Reijke1, P C Vos, E C de Boer, R F Bevers, W H de Muinck Keizer, K H Kurth, D H Schamhart.   

Abstract

The study was initiated as an in vitro approach to the situation existing during intravesical bacillus Calmette-Guerin (BCG) instillation in patients with superficial bladder cancer. Cytokine secretion of a human bladder carcinoma cell line T24 treated with BCG was investigated. A 24-h treatment of T24 cells with BCG resulted in a tenfold higher secretion of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF alpha) when compared with T24 cells treated with Escherichia coli, Streptococcus faecalis or a cell wall preparation of Nocardia rubra (N-CWS). No secretion of IL-1 beta and IL-2 was detected. Pre-exposing T24 cells to BCG for various periods of time indicated that a minimum exposure time of 0.5-1 h was required to upregulate IL-6 and TNF alpha production. Extending the BCG pre-exposure time to 2 and 3 h further increased the rate of cytokine production. No significant difference was found, however, between the rate of secretion initiated after a 2-h or 3-h pre-exposure period. The amounts of these cytokines secreted in the presence of BCG-conditioned medium did not differ significantly from the constitutively secreted amounts, excluding an effect of products possibly secreted by BCG on the upregulation of IL-6 and TNF alpha. In addition, upregulation of cytokine production appeared to be dependent on the concentration of BCG. The results suggest that cytokines may be produced by urothelial tumor cells after intravesical instillation in patients with superficial bladder cancer, which may play a role in the mode of action of BCG.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8279092     DOI: 10.1007/bf00296835

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  23 in total

1.  Internalization of bacille Calmette-Guerin by bladder tumor cells.

Authors:  M J Becich; S Carroll; T L Ratliff
Journal:  J Urol       Date:  1991-06       Impact factor: 7.450

2.  Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen.

Authors:  J Bubeník; M Baresová; V Viklický; J Jakoubková; H Sainerová; J Donner
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

3.  Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.

Authors:  L R Kavoussi; E J Brown; J K Ritchey; T L Ratliff
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

4.  Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy.

Authors:  S Prescott; K James; T B Hargreave; G D Chisholm; J F Smyth
Journal:  J Urol       Date:  1990-11       Impact factor: 7.450

Review 5.  Tumour necrosis factor: a cytokine with multiple biological activities.

Authors:  G Semenzato
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

6.  Cytokine production by the bladder carcinoma cell line 5637: rapid analysis of mRNA expression levels using a cDNA-PCR procedure.

Authors:  J G Kaashoek; R Mout; J H Falkenburg; R Willemze; W E Fibbe; J E Landegent
Journal:  Lymphokine Cytokine Res       Date:  1991-06

7.  Mycobacterial adherence and BCG treatment of superficial bladder cancer.

Authors:  D H Schamhart; E C de Boer; R F Bevers; K H Kurth; P A Steerenberg
Journal:  Prog Clin Biol Res       Date:  1992

8.  Comparative studies of glucose metabolism in HTC, RLC, MH1C1, and Reuber H35 rat hepatoma cells.

Authors:  D H Schamhart; K W van de Poll; R van Wijk
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

9.  Interleukin 6 (IL-6) in serum and urine of renal transplant recipients.

Authors:  M H Van Oers; A A Van der Heyden; L A Aarden
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

10.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

View more
  16 in total

Review 1.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

2.  Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo.

Authors:  Y Luo; X Chen; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 3.  Neuroimmune mechanisms in health and disease: 2. Disease.

Authors:  H Anisman; M G Baines; I Berczi; C N Bernstein; M G Blennerhassett; R M Gorczynski; A H Greenberg; F T Kisil; R D Mathison; E Nagy; D M Nance; M H Perdue; D K Pomerantz; E R Sabbadini; A Stanisz; R J Warrington
Journal:  CMAJ       Date:  1996-10-15       Impact factor: 8.262

4.  A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein.

Authors:  Y Luo; A Szilvasi; X Chen; W C DeWolf; M A O'Donnell
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

5.  Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy.

Authors:  Patrick Gellings; Michelle Galeas-Pena; Lisa A Morici
Journal:  Clin Exp Med       Date:  2022-01-25       Impact factor: 3.984

6.  BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis.

Authors:  Katja Schwarzer; Martin Foerster; Thomas Steiner; Inge-Marie Hermann; Eberhard Straube
Journal:  Cancer Cell Int       Date:  2010-06-29       Impact factor: 5.722

Review 7.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

8.  Interaction between bacteria and the lumenal bladder surface: modulation by pentosan polysulfate, an experimental and theoretical approach with clinical implication.

Authors:  D H Schamhart; E C de Boer; K H Kurth
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 9.  Toll-like receptors in urothelial cells--targets for cancer immunotherapy.

Authors:  Hélène LaRue; Cherifa Ayari; Alain Bergeron; Yves Fradet
Journal:  Nat Rev Urol       Date:  2013-08-27       Impact factor: 14.432

Review 10.  BCG: a vaccine with multiple faces.

Authors:  Marco Antonio Yamazaki-Nakashimada; Alberto Unzueta; Luisa Berenise Gámez-González; Napoleón González-Saldaña; Ricardo U Sorensen
Journal:  Hum Vaccin Immunother       Date:  2020-01-29       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.